Drug resistance in Mycobacterium tuberculosis. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Drug resistance in Mycobacterium tuberculosis.

Eur Respir J Suppl. 1995 Sep;20:701s-713s. Unique Identifier : AIDSLINE MED/96163838
Cole ST; Telenti A; Unite de Genetique Moleculaire Bacterienne, Institut; Pasteur, Paris, France.

Abstract: During the last decade, there has been a marked increase in the number of gravity of tuberculosis cases both in developing countries and in industrialized nations. This is, in part, due to the acquired immune deficiency syndrome (AIDS) pandemic, but global economic depression, increased homelessness and declining control programmes have also contributed. One of the more insidious consequences of this resurgence has been the recent emergence and nosocomial transmission of multidrug-resistant strains of Mycobacterium tuberculosis, thus raising the possibility that untreatable forms of the disease may become widespread. Somewhat surprisingly, given the difficulties of working with this slow-growing pathogen, remarkable progress has been made in a relatively short time, in understanding the molecular epidemiology, the genetic basis, and the biochemical mechanisms of drug resistance. Furthermore, a number of promising molecular tools are now available to help counter tuberculosis and to further understanding.
Keywords: Amino Acid Sequence/GENETICS Antitubercular Agents/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/*DRUG THERAPY/TRANSMISSION Cross Infection/DRUG THERAPY/TRANSMISSION Developing Countries Drug Resistance, Multiple/GENETICS Human Microbial Sensitivity Tests Molecular Sequence Data Mycobacterium tuberculosis/*DRUG EFFECTS/GENETICS Polymerase Chain Reaction Rifampin/THERAPEUTIC USE Risk Factors Support, Non-U.S. Gov't Tuberculosis, Multidrug-Resistant/*DRUG THERAPY/TRANSMISSION Tuberculosis, Pulmonary/*DRUG THERAPY/TRANSMISSION JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL

KWDaminoacidsequence/geneticsantitubercularagents/KWDtherapeuticuseaids-relatedopportunisticinfections/KWDdrugtherapy/transmissioncrossinfection/drugtherapy/transmissiondevelopingcountriesdrugresistance,multiple/geneticshumanmicrobialsensitivitytestsmolecularsequencedatamycobacteriumtuberculosis/KWDdrugeffects/geneticspolymerasechainreactionrifampin/therapeuticuseriskfactorssupport,non-uKWDsKWDgov'ttuberculosis,multidrug-resistant/KWDdrugtherapy/transmissiontuberculosis,pulmonary/KWDdrugtherapy/transmissionjournalarticlereviewreview,tutorial
960630
M9660772

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .